The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2 disease will be enrolled. Participants, who have already reached end-stage renal disease (ESRD), will provide retrospective chart review data and biological specimens at baseline only. Other participants, in addition to retrospective chart review, will be followed prospectively.
Refer to www.studyALECT2.com
Study Type
OBSERVATIONAL
Enrollment
26
Clinical Trial Site
Change in Estimated Glomerular Filtration Rate (eGFR) from Baseline Up to End of Study (Month 48)
Time frame: Baseline (Day 1), Months 6, 12, 18, 24, 30, 36, 42 and 48
Time to End-Stage Renal Disease (ESRD)
Time frame: From baseline to end of study (Month 48)
Level of Leukocyte Chemotactic Factor 2 (LECT2) Messenger Ribonucleic Acid (mRNA) in Blood
Time frame: Baseline (Day 1), Months 6, 12, 18, 24, 30, 36, 42 and 48
Level of LECT2 mRNA in Urine
Time frame: Baseline (Day 1), Months 12, 24, 36 and 48
Level of LECT2 Protein in Blood
Time frame: Baseline (Day 1), Months 6, 12, 18, 24, 30, 36, 42 and 48
Level of LECT2 Protein in Urine
Time frame: Baseline (Day 1), Months 12, 24, 36 and 48
Percentage of Participants With Proteinuria
Time frame: Baseline (Day 1), Months 12, 24, 36 and 48
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Scottsdale, Arizona, United States
Clinical Trial Site
Tucson, Arizona, United States
Clinical Trial Site
Denver, Colorado, United States
Clinical Trial Site
Chicago, Illinois, United States
Clinical Trial Site
Indianapolis, Indiana, United States
Clinical Trial Site
Baltimore, Maryland, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Detroit, Michigan, United States
Clinical Trial Site
Rochester, Minnesota, United States
Clinical Trial Site
Albuquerque, New Mexico, United States
...and 21 more locations